Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00216866
Other study ID # R-02-191
Secondary ID
Status Completed
Phase Phase 2
First received September 19, 2005
Last updated August 25, 2017
Start date September 2002
Est. completion date March 2006

Study information

Verified date August 2017
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein thrombosis (UEDVT) in patients treated with dalteparin and warfarin.

Anticoagulation with dalteparin and warfarin in patients with UEDVT secondary to central venous catheters in patients with an active malignancy is an effective therapy as quantified by the success of catheter preservation. A prolonged line salvage rate without a recurrence of UEDVT will improve the management of cancer patients who develop upper extremity deep venous thrombosis in the setting of a central venous (CV) catheter.


Description:

Deep venous thrombosis (DVT) is a serious disorder with an annual incidence of approximately 0.1% and increasing with age to 1% in the elderly. Deep venous thrombosis of the upper extremity (UEDVT) is estimated to constitute 1-5% of all cases of DVT.

The therapy of UEDVT has not been standardized.Therapeutic options include anticoagulation with unfractionated heparin followed by warfarin, treatment with a thrombolytic agent, or a thrombectomy. Recently, treatment with low molecular weight heparin has been shown to be a safe and effective treatment for patients with verified UEDVT.

In patients with cancer, treatment of UEDVT associated with central venous catheters is even less standardized. Some groups advocate removal of the catheter as the sole treatment for the DVT, others remove the catheter and treat the DVT. A major disadvantage to removing the line is that often re-insertion in the opposite limb is then required to avoid disruption of chemotherapeutic treatment. This reinsertion again puts the patient at risk for thrombosis and pulmonary embolism. Another therapy is treatment only with systemic thrombolytic therapy. The disadvantage of thrombolytic therapy in persons with cancer is that there is a high risk for major bleeding at the doses used.

A treatment regimen that has been adopted by the London Health Sciences Centre, and others across Canada, is to leave the catheter in place and treat the DVT with low molecular weight heparin and warfarin. This regimen is believed to halt the progression of thrombi, prevent embolism and allow natural thrombolytic mechanisms to work effectively. By leaving the central line in situ and appropriately treating the thrombosis there is no disruption in the delivery of life-prolonging or life-saving treatment in the form of chemotherapy.

Preliminary data has been collected over the past 24 months at the London Health Sciences Centre; the results suggest that this approach to treatment will prove to be beneficial to the patient. Thirteen (13) patients with cancer and an UEDVT associated with a central venous catheter were treated with dalteparin and warfarin with an intention to leave the central line in situ. Of the 13, 1 patient had the line removed after 3 days at a peripheral hospital against recommendation. The UEDVT was treated successfully and without the need for line removal in 9 (75%) of the remaining 12 patients. Two (2) of the 12 had lines removed at 1 week and 1 had the line removed at 4 weeks due to worsening symptoms of UEDVT.

Therefore, UEDVT is a more common and less benign disease than previously reported and generally arises in the presence of recognizable risk factors such as central venous catheters and cancer. Treatment of the UEDVT with dalteparin and warfarin will treat the thrombosis while preserving the central venous access for continued use. Hence, the need for additional catheters and subsequent risk of bilateral UEDVT will be minimized.

Result of the CLOT (Clot in Cancer) Trial have shown the superiority of treatment with dalteparin for 6 months as compared to the conventional treatment with short-term dalteparin and extended warfarin for cancer patients with acute symptomatic DVT or PE. Extended anticoagulant therapy may be beneficial in patients with UEDVT as well, however, there are currently no estimates of clinical outcomes for either conventional (dalteparin followed by warfarin) or extended therapy with dalteparin in this patient population.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date March 2006
Est. primary completion date March 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Males or females greater than or equal to 18 years of age, inclusive.

- Symptomatic acute upper limb thrombosis with or without pulmonary embolism associated with central venous catheter objectively documented by compression ultrasonography, venogram or computed tomography (CT) scan.

- Diagnosis of active malignancy, as defined by patients who are either receiving active treatment, or have metastatic disease or who have been diagnosed within the past two years.

- Willing to provide written informed consent.

Exclusion Criteria:

- Dialysis catheters.

- Active bleeding or high risk for major bleeding.

- Platelet count < 100 x 10x9/L.

- Serum creatinine > 177umol/L

- Currently on warfarin with therapeutic intent (does not include minidose warfarin used as prophylaxis for CV catheter thrombosis).

- Pulmonary embolism accompanied by hemodynamic instability or oxygen requirement.

- Inability to infuse through the catheter after a trial of intraluminal thrombolytic therapy.

- Patients with acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) with a bone marrow or stem cell transplant pending in next 3 months.

Study Design


Intervention

Drug:
Dalteparin

Warfarin


Locations

Country Name City State
Canada Queen Elizabeth II Health Care Centre Halifax Nova Scotia
Canada St. Joseph's Healthcare Hamilton Ontario
Canada London Health Sciences Centre London Ontario
Canada Sir Mortimer B. Davis Jewish General Hospital Montreal Quebec
Canada Ottawa Civic Hospital Ottawa Ontario
Canada Ottawa General Hospital Ottawa Ontario

Sponsors (2)

Lead Sponsor Collaborator
Lawson Health Research Institute Pfizer

Country where clinical trial is conducted

Canada, 

References & Publications (9)

Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med. 2002 Jun 18;136(12):865-72. Erratum in: Ann Intern Med. 2003 Mar 4;138(5):438. — View Citation

Elliott G. Upper-extremity deep vein thrombosis. Lancet. 1997 Apr 26;349(9060):1188-9. — View Citation

Kommareddy A, Zaroukian MH, Hassouna HI. Upper extremity deep venous thrombosis. Semin Thromb Hemost. 2002 Feb;28(1):89-99. Review. — View Citation

Kooij JD, van der Zant FM, van Beek EJ, Reekers JA. Pulmonary embolism in deep venous thrombosis of the upper extremity: more often in catheter-related thrombosis. Neth J Med. 1997 Jun;50(6):238-42. — View Citation

Kovacs MJ, Anderson DA, Wells PS. Prospective assessment of a nomogram for the initiation of oral anticoagulation therapy for outpatient treatment of venous thromboembolism. Pathophysiol Haemost Thromb. 2002 May-Jun;32(3):131-3. — View Citation

Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001;106(1-2):69-72. Review. — View Citation

Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llamazares JF. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost. 1994 Oct;72(4):548-50. — View Citation

Savage KJ, Wells PS, Schulz V, Goudie D, Morrow B, Cruickshank M, Kovacs MJ. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost. 1999 Sep;82(3):1008-10. — View Citation

Volturo GA, Repeta RJ Jr. Non-lower extremity deep vein thrombosis. Emerg Med Clin North Am. 2001 Nov;19(4):877-93, vi. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint of the study will be rate of central line failure, defined as infusion failure that does not respond to 2mg tissue plasminogen activator (tPA), within the 3 months of study follow-up.
Secondary The secondary endpoints include recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE), major bleeding and death, time to central line failure.
See also
  Status Clinical Trial Phase
Recruiting NCT04304651 - Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism N/A
Recruiting NCT05907564 - Aventus Thrombectomy System Pulmonary Embolism Clinical Study N/A
Completed NCT05128591 - A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091 Phase 1
Completed NCT00670540 - Epidemiology of Thromboembolism Disease: A Cohort Study N/A
Recruiting NCT04263038 - Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism Phase 4
Recruiting NCT04388657 - COVID-19, bLOod Coagulation and Thrombosis
Completed NCT04439383 - Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
Completed NCT01897103 - Platelet Activity in Vascular Surgery for Thrombosis and Bleeding N/A
Recruiting NCT04657120 - Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy N/A
Completed NCT02720328 - Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Phase 4
Completed NCT01203098 - A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty Phase 2
Completed NCT00830570 - The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings N/A
Recruiting NCT05568966 - Collection of Blood Samples for New Diagnostic Devices 2 N/A
Not yet recruiting NCT06209892 - Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis N/A
Completed NCT01086215 - Registry of AngioJet Use in the Peripheral Vascular System N/A
Completed NCT02996851 - Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs N/A
Completed NCT00119457 - Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial) Phase 2
Recruiting NCT05853796 - Observational Dutch Young Symptomatic StrokE studY - nEXT
Terminated NCT02610608 - Medical Assistance for the Procreation and Risk of Thrombosis.
Completed NCT04368377 - Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 Phase 2